A Phase 12a Study of Subcutaneous MET233 Combined with MET097 for Treating Adults with Overweight or Obesity, Including Those with Type 2 Diabetes

What this Trial Is About

Researchers are studying how well the combination of MET233 and MET097 works to treat adults who are overweight or have obesity, including some with type 2 diabetes. This is a randomized, placebo-controlled, double-blind study focusing on safety, tolerability, and how the drugs behave in the body. The study includes adults with a body mass index BMI between 27 and 45 kgm2, with certain parts including participants with type 2 diabetes. The study has several parts A, B, C, D, E, and G with different dosing schedules. Participants receive subcutaneous under the skin doses of MET233 combined with MET097 or a matching placebo. Some parts involve single ascending doses, others multiple weekly or monthly doses. After each treatment phase, there is a safety follow-up period lasting from about 12 weeks up to 11 weeks depending on the part. Participants will be monitored through scheduled visits including physical exams, lab tests, ECGs, and assessments of body weight changes. Researchers will track treatment-emergent adverse events and measure drug concentrations in the blood after dosing. The total study participation varies by part but includes screening, treatment doses, and extended safety follow-up periods. Participants need to comply with all study procedures and assessments throughout the study.

A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes